Filing summary
Company and period: The supplied filing is Leap Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2019, not a filing identified as Cypherpunk Technologies Inc. The registrant-name discrepancy should be verified. Leap is a clinical-stage biopharmaceutical company developing cancer therapies; it reported no product revenue.
Financial performance and position
| Metric | Q3 2019 | First nine months 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.8 million | $18.7 million |
| General and administrative expense | $2.2 million | $6.5 million |
| Net loss | $7.9 million | $24.9 million |
| Net loss per share, basic | $0.33 | $1.15 |
| Operating cash used | Not separately presented | $21.0 million |
Margins are not meaningful because the company had no revenue. At September 30, cash and cash equivalents were $10.1 million; total assets were $14.1 million, total liabilities $8.6 million, and stockholders’ equity $5.6 million. Liabilities included $1.2 million of lease obligations; the filing does not report borrowings as debt. Cash declined $6.2 million from year-end 2018. Financing activities provided $14.8 million during the first nine months.
Changes versus comparable periods
- Q3 operating expenses fell $0.7 million year over year, mainly from lower clinical-trial, manufacturing, and consulting costs. Net loss nevertheless increased from $6.6 million to $7.9 million, partly because Q3 2018 included a $1.8 million warrant fair-value gain and 2019 had a net expense from Australian R&D incentive adjustments.
- Nine-month operating expenses increased $3.4 million to $25.2 million, with R&D up $3.8 million as clinical-trial costs and enrollment increased. Net loss was $24.9 million versus $24.6 million in 2018; prior-year warrant remeasurement effects make the comparison less directly indicative of operating trends.
- Common shares outstanding rose from 14.7 million at December 31, 2018 to 24.2 million at September 30, 2019, reflecting financing activity and other share issuances.
Outlook, developments, and risks
- Management stated that substantial doubt exists about the company’s ability to continue as a going concern for one year after the financial statements were issued, citing the need for additional capital and uncertainty about raising it. The company expects continued operating losses.
- Leap said it expected $0.8 million of Australian R&D incentive payments in 2019. It reported a right to sell up to $20 million of stock to Lincoln Park, subject to conditions, and had completed a $1.0 million sale to Lincoln Park. It also raised $12.1 million net in a February 2019 public offering and $1.9 million through an ATM program during the nine-month period.
- Enrollment in a TRX518 clinical trial was suspended pending funding; management reprioritized resources toward DKN-01. The filing says the reprioritization was not prompted by safety or efficacy concerns. If additional funding or cost-sharing is unavailable, Leap may delay, reduce, or eliminate trials and research programs.
- Management reported DKN-01 clinical activity in several cancer settings, including exploratory combination-study results; these are investigational findings, not established efficacy. DKN-01 and TRX518 had not been approved by the FDA.
- Risks include clinical-trial outcomes and timing, regulatory approval, funding availability and dilution, competition, and intellectual-property challenges. Two European patent matters concerning TRX518 remained on appeal; one challenged patent had been revoked by the EPO opposition division.
Investor verification points
- Confirm the issuer identity: the request names Cypherpunk Technologies Inc., while the filing text identifies Leap Therapeutics, Inc. (Nasdaq: LPTX).
- Review subsequent financing, cash burn, and management’s assessment of liquidity and going-concern status; this filing does not provide a specific cash-runway estimate.
- Check the status and funding of DKN-01 trials and the suspended TRX518 enrollment, including whether clinical findings were confirmed in larger studies.
- Assess potential dilution from outstanding warrants, options, equity programs, and the Lincoln Park facility; the filing listed 10.4 million warrant shares outstanding.
- Track the pending EPO appeals and any resulting changes to TRX518 patent protection.